Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor

Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: To examine the safety and tolerability of dasatinib in patients with operable TNBC To explore potential intracellular mechanisms which impact dasatinib effect on cellular localization of EGFR in operable TNBC. To examine the pathologic complete response (pCR) rates to standard neoadjuvant chemotherapy in nEGFR+ TNBC To examine breast cancer recurrence rates and patterns of metastatic recurrent in nEGFR+ TNBC

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Recruitment

Summary

Participation Requirements

Description

Tracking Information